Rosuvastatin 2.5mg/Ezetimibe, Hanmi from Daewoong,& Yuhan

It reduces the side effects of statins and is similar to the high dose of a single drug

Hanmi Rosuzet 10/2.5mg monthly Rx growth of 1.4 Billion won

Rosuzet 10/2.5 mg (left) and Daewoong Crezet 10/2.5 mg (right)

The combination market, which combines low-dose (2.5 mg) Rosuvastatin + Ezetimibe, is fluctuating with the addition of large pharmaceutical companies.

 

Yuhan Corporation will also join the market, which Hanmi Pharmaceutical first entered at the end of 2021, following Daewoong Pharmaceutical.

 

As the market size is not expected to be small, competition between the three pharmaceutical companies is expected to intensify.

 

According to the industry on the 9th, Yuhan received a license for Rosuvastatin 2.5mg + Ezetimibe complex developed by its affiliate Addpharma and received a license for Rosuvamibe 10/2.5mg on the 7th.

 

Earlier, the original developer Addpharma has also licensed for Addrose 10/2.5mg in December last year.

 

However, it is said that this product has not yet been applied.

 

Rosuvastatin + Ezetimibe complex has become a trend in the treatment market for dyslipidemia.

 

It is characterized by the combination of statins and Ezetimibe to increase the therapeutic effect.

 

However, there has been a steady demand for low capacity due to the burden of existing statins.

 

The Rosuvastatin 2.5 mg + Ezetimibe complex has the advantage of reducing side effects of high-dose statins such as diabetes-induced and muscular dystrophy while having a similar effect to a single drug, high-dose Rosuvastatin.

 

Accordingly, it is becoming a new prescription option for patients with low and moderate-risk groups and elderly patients.

 

Hanmi Pharmaceutical pioneered the market by launching Rosuzet 10/2.5 for the first time in Korea in December 2021.

 

This product is known to have shown a blockbuster aspect as its monthly prescription (based on Ubist) has recently risen to about 1.4 billion won.

 

Daewoong Pharmaceutical then joined the market by releasing Crezet 10/2.5mg in November last year.

 

There is little difference in the drug prices of the two products.

 

Rosuzet 10/2.5 mg is 751 won and Crezet 10/2.5 mg is 750 won.

 

It's only a one-won difference.

 

Yuhan is expected to be on the payroll list in May with permission this time.

 

As the three pharmaceutical companies have a high market share in the Rosuvastatin+Ezetimibe combination market, market reactions are expected to be high.

 

Last year, Rosuzet recorded 140.3 billion won, Crezet 25.8 billion won, and Rosuvamibe 66.8 billion won in outpatient prescriptions.

 

They are expected to implement a strategy to maximize sales through the Rosuvastatin+Ezetimibe.

 

Meanwhile, in addition to these three companies, other pharmaceutical companies such as NVP Healthcare are also said to have jumped into the development of Rosuvastatin 2.5mg + Ezetimibe complex.

 

It is also leading to the development of Atorvastatin low-dose + Ezetimibe complex.